ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2283

Arrhythmia Risk in Diabetic Rheumatoid Arthritis Patients: Comparative Analysis of IL-6 Inhibitors versus TNF-α Inhibitors
Abstract Number: 2284

Cardiovascular Outcomes in Diabetic Rheumatoid Arthritis Patients: TNF-α Inhibitors versus IL-6 Inhibitors
Abstract Number: 2285

Synovium-on-a-chip – Development of a Humanized Rheumatoid Arthritis Model that Mimics Disease and Patient Biological Heterogeneity
Abstract Number: 2286

Association of Semaglutide Prescription with Improved Joint Outcomes in Rheumatoid Arthritis Patients
Abstract Number: 2287

Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
Abstract Number: 2288

Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial
Abstract Number: 2289

Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Disease Activity in Patients with Rheumatoid Arthritis: A Pilot Study
Abstract Number: 2290

Patterns and Predictors of Clinical Improvement in Patients with Sjögren’s Disease: A Longitudinal Analysis of ESSDAI and ESSPRI Improvements
Abstract Number: 2291

Correlation and Concordance Between the Oxford Grading Scale, Ocular Staining Score, and van BijsterveldScore in the diagnosis of Sjögren’s Disease
Abstract Number: 2292

Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
Abstract Number: 2293

CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
Abstract Number: 2294

Comparative Analysis of Patients Included in Trials Utilizing Biologic Drugs in the Treatment of Primary Sjögren’s Syndrome
Abstract Number: 2295

Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI
Abstract Number: 2296

Evaluation of the Dual Mode of Action of Ianalumab (VAY736) in the Circulation and Salivary Gland Tissue of Patients With Sjögren’s Disease: Results From a Phase 2 Mechanistic Study
Abstract Number: 2297

Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjogren’s Disease Treated with Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].